Sales of statins are forecast to drop from $13.7 billion in 2012 to $5.5 billion in 2021, despite retaining a 59% share of the dislipidemia patient population. The sales slump will be due to payers pushing for generic usage and the low switching costs associated with this, according to new analysis by Datamonitor Healthcare, Forecast: Dislipidemia .
Launches of dislipidemia pipeline products are expected to lead to a slight increase in sales at the end of the forecast period 2012-2021 across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK)
